Home › Funds › Remedium Capital Partners, LLC › SYRE
Remedium Capital Partners, LLC position in SYRE
SPYRE THERAPEUTICS INC · Health Care
Remedium Capital Partners, LLC reported holding 1,160,620 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$103.3M, representing 37.77% of its reported portfolio and ranking #1 among its reported holdings. Remedium Capital Partners, LLC has disclosed SYRE holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Remedium Capital Partners, LLC's SYRE position evolved
Remedium Capital Partners, LLC first disclosed a stake in SYRE in Q4 2025 at 1,456,231 shares (US$47.7M). The position peaked in Q2 2026 at 1,464,169 shares, worth US$130.0M. Across 4 filings, Remedium Capital Partners, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,160,620 shares valued at US$103.3M — a reduction of -303,549 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.46M | $47.71M | New |
| Q1 2026 | 1.46M | $73.45M | Hold |
| Q2 2026 | 1.46M | $129.99M | Add |
| Q3 2026 | 1.16M | $103.33M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SYRE and 13F data
SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 66 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SYRE
- PERCEPTIVE ADVISORS LLC 4.32M sh · $383.48M · Q2 2026
- RTW INVESTMENTS, LP 4.25M sh · $377.49M · Q2 2026
- Paradigm Biocapital Advisors LP 3.84M sh · $340.98M · Q2 2026
- Venrock Adviser, LLC 2.99M sh · $265.05M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.80M sh · $248.51M · Q2 2026
- TCG Crossover Management, LLC 1.90M sh · $168.73M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M sh · $167.99M · Q2 2026
- Affinity Asset Advisors, LLC 1.28M sh · $113.56M · Q2 2026
- BRAIDWELL LP 879.47K sh · $78.08M · Q2 2026
- Siren, L.L.C. 868.60K sh · $77.33M · Q3 2026
- Commodore Capital LP 846.79K sh · $75.18M · Q2 2026
- EMERALD ADVISERS, LLC 571.05K sh · $50.84M · Q3 2026
More on Remedium Capital Partners, LLC
FAQ
How long has Remedium Capital Partners, LLC held SYRE?
Remedium Capital Partners, LLC has disclosed SYRE holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Remedium Capital Partners, LLC's current position in SYRE?
As of Q3 2026, Remedium Capital Partners, LLC holds 1.16M shares of SYRE (SPYRE THERAPEUTICS INC), valued at $103.33M, representing 37.77% of its reported portfolio and ranking #1.
Has Remedium Capital Partners, LLC been buying or selling SYRE?
In the latest 13F filing (Q3 2026), Remedium Capital Partners, LLC reduced its position in SYRE. The position peaked in Q2 2026 at 1.46M shares.
Which other funds hold SYRE?
Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 66 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.